Edwards Lifesciences (EW) Tops Q3 EPS by 9c, Q4 & FY Guidance Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Wall Street gains as healthcare stocks rally, oil prices fall
- Brent hits five-month high as attacks on ships, Saudi sites fuel supply worries
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
- Cerebras Systems falls as TD Cowen cuts price target
- Nasdaq climbs as chip and AI-linked stocks bounce back
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
- 3M issues warrant to Amazon in $6B data center product deal
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
Edwards Lifesciences Reports Third Quarter Results
October 26, 2015 4:15 PM EDTIRVINE, Calif., Oct. 26, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported financial results for the quarter ended September 30, 2015.
Highlights for the third quarter of 2015 as compared to the third quarter of 2014:
Global sales grew 1.3% to $615.5 million, and underlying1 sales were up 13.6%. Global THV sales grew 10.8% to $296.1 million, and underlying sales were up 29.4%. The U.S. rollout of the Edwards SAPIEN 3... More


